1952.HK
Everest Medicines Limited [1952.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1952.HK Stock Summary
Top 10 Correlated ETFs
1952.HK
Top 10 Correlated Stocks
1952.HK
In the News
1952.HK Financial details
Company Rating
-
Market Cap
8.36B
Income
-2.85M
Revenue
20.64M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
432
Optionable
No
Shortable
Yes
Earnings
04 Mar 2024
P/E
-21.71
Forward P/E
-
PEG
-
P/S
451.85
P/B
0.95
P/C
-
P/FCF
-3.64
Quick Ratio
3.91
Current Ratio
3.92
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-76.01%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-18.11%
SMA50
19.13%
SMA100
26.36%
Inst Own
-
Inst Trans
-
ROA
-4%
ROE
-4%
ROC
-0.24%
Gross Margin
64%
Oper. Margin
-10946%
Profit Margin
-1933%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.32-32.2
52W High
+53.91%
52W Low
+392.5%
RSI
49.59
Rel Volume
1.2
Avg Volume
4.45M
Volume
5.32M
Perf Week
4.56%
Perf Month
-5.56%
Perf Quarter
58.87%
Perf Half Y
49.92%
-
-
-
-
Beta
2.16
-
-
Volatility
1.71%, 6.27%
Prev Close
0.61%
Price
49.25
Change
8.24%
Company Profile
- Volume Average 4.45M
- Market Capitalization 8.36B
- Employee 432
- CEO Mr. Yongqing Luo
- Headquarters Shanghai,CN
- IPO Date 2020-10-09
-
Website
https://www.everestmedicines.com 
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017 and is headquartered in Shanghai, China.
